Daily Endocrinology Research Analysis
Analyzed 112 papers and selected 3 impactful papers.
Summary
Three high-impact studies span developmental genetics, vascular-metabolic crosstalk, and multi-receptor pharmacology. A JCI report defines a HER2-deficiency developmental syndrome (GRACE) and flags pregnancy risk with HER2 inhibitors; an ATVB study shows endothelial DNA damage driving cardio-kidney-metabolic dysfunction via ET-1/ETAR-ACSS2 with drug reversibility; and a Nature paper demonstrates that GLP-1R–GIPR–PPARα/γ/δ quintuple agonism robustly corrects obesity and diabetes in mice.
Research Themes
- Developmental genetics and teratogenic risk in HER2 signaling
- Endothelial DNA damage as a driver of cardio-kidney-metabolic dysfunction
- Poly-agonist incretin–nuclear receptor pharmacology for obesity and diabetes
Selected Articles
1. HER2 deficiency causes a developmental disorder with growth retardation and craniofacial malformations.
Through multi-species functional validation, rare germline HER2 loss-of-function variants were shown to cause a human developmental syndrome (GRACE) with growth retardation and craniofacial malformations. Maternal exposure to a HER2 inhibitor reproduced similar defects in mice, highlighting a teratogenic risk of HER2-targeted therapy during pregnancy.
Impact: This paper redefines HER2 biology by demonstrating an essential developmental role and establishes a new syndrome with immediate implications for genetic diagnosis and drug safety in pregnancy.
Clinical Implications: Genetic testing for HER2 variants should be considered in patients presenting with syndromic orofacial clefts and growth retardation; HER2-targeted therapies should be avoided during pregnancy due to potential teratogenicity.
Key Findings
- Five rare germline HER2 variants were identified in unrelated families with growth and craniofacial anomalies from a 720-family cleft cohort.
- Variants impaired HER2 stability/localization/phosphorylation and reduced ERK signaling in cells; Xenopus assays failed to rescue development.
- Knock-in mice harboring a patient variant and mice with maternal tucatinib exposure recapitulated growth retardation and craniofacial defects.
- Defines GRACE syndrome and implicates HER2 as essential for human growth and craniofacial morphogenesis; warns of pregnancy risk with anti-HER2 drugs.
Methodological Strengths
- Cross-species functional validation (cell, Xenopus, knock-in mouse) linking genotype to phenotype
- Integration of human exome sequencing with mechanistic assays and pharmacologic exposure models
Limitations
- Number of affected families with HER2 variants was small (n=5)
- Human pregnancy risk inference is based on mouse exposure models and requires clinical corroboration
Future Directions: Establish registries for pregnancy outcomes with HER2-targeted therapies; delineate genotype–phenotype correlations and variant penetrance; explore safe therapeutic alternatives during pregnancy.
The human epidermal growth factor receptor 2 (HER2) is a major therapeutic target in cancer. While the oncogenic effects of HER2 hyperactivation are well-characterized, the biological consequences of its deficiency remain poorly defined. Here, through exome sequencing analyses of a cohort of 720 families affected by isolated or syndromic orofacial clefts, we unexpectedly identified five distinct rare germline HER2 variants in five unrelated families with growth deficits, orofacial clefts, and other craniofacial, skeletal, and auditory anomalies. In Xenopus embryos, these variants failed to recapitulate the developmental effects of wild-type HER2. In cultured cells, they disrupted HER2 protein stability, membrane localization, or site-specific phosphorylation, resulting in diminished ERK signaling. Strikingly, knock-in mice expressing a patient-derived HER2 variant and mice maternally exposed to Tucatinib, a recently approved anti-HER2 drug, both replicated patient phenotypes: retarded growth and diverse craniofacial abnormalities, including ocular dysgenesis, short jaws, and cleft palate. Collectively, our findings define a developmental disorder that we designate GRACE syndrome (Growth Retardation and Craniofacial Malformations Caused by HER2 Deficiency), establish HER2's essential role in human growth and craniofacial morphogenesis, and reveal that HER2-targeted therapies during pregnancy can induce craniofacial defects and lifelong growth impairment in fetuses. 5.
2. GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice.
A multi-receptor approach combining incretin (GLP-1R, GIPR) with nuclear receptor (PPARα/γ/δ) agonism yielded profound weight loss and glycemic correction in murine models. The work showcases a next-generation poly-agonist strategy with potential to surpass current incretin-based therapies.
Impact: Demonstrates a paradigm-advancing poly-agonist framework that integrates complementary metabolic pathways to correct obesity and diabetes.
Clinical Implications: If translated safely, quintuple agonism may provide greater efficacy in weight reduction and glycemic control than current incretin monotherapies or dual agonists, but human safety (e.g., PPAR-related effects) must be rigorously evaluated.
Key Findings
- Quintuple agonism targeting GLP-1R, GIPR, and PPARα/γ/δ produced robust weight loss and improved glycemia in murine obesity/diabetes models.
- Poly-agonist design leverages complementary mechanisms (appetite, insulin secretion, lipid oxidation) to enhance efficacy.
- Findings position multi-receptor pharmacology as a next-generation approach beyond dual incretin agonists.
Methodological Strengths
- Use of rigorous murine metabolic phenotyping across obesity/diabetes models
- Rational poly-agonist design integrating incretin and nuclear receptor pathways
Limitations
- Preclinical evidence limited to animal models; human translational efficacy and safety unknown
- Potential PPAR-related off-target or long-term adverse effects require careful evaluation
Future Directions: Advance to non-human primate and early-phase human studies to evaluate efficacy, safety, and dose-finding, with mechanistic biomarkers to deconvolute pathway contributions.
There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R-GIPR co-agonism is effective in the management of obesity and type 2 diabetes
3. Endothelial DNA Damage Orchestrates Cardio-Kidney-Metabolic Dysfunction Through Endothelin-1 Signaling.
EC-specific DNA damage under high-fat diet precipitated hypertension, dyslipidemia, steatosis, visceral adiposity, and renal aging via an ET-1→ETAR→ACSS2 axis; pharmacologic ETAR blockade reversed these phenotypes. Human biopsy correlations support translational relevance of the endothelial damage signature.
Impact: Identifies a unifying endothelial damage–endothelin mechanism across cardiovascular, hepatic, adipose, and renal pathology with immediate therapeutic implications using an approved ETAR antagonist.
Clinical Implications: Supports testing ETAR blockade (e.g., atrasentan) in cardio-renal-metabolic endotypes characterized by endothelial DNA damage signatures; motivates biomarker-driven patient stratification.
Key Findings
- Endothelial DNA double-strand breaks under HFD induced ET-1 secretion, hepatic hypoxia, ETAR activation, ACSS2 upregulation, and systemic metabolic/renal dysfunction.
- Atrasentan normalized blood pressure, reduced hepatic steatosis and visceral fat, restored HDL-C, and attenuated renal aging in mice.
- In human kidney biopsies, endothelial DNA damage markers correlated with worse eGFR, lower HDL-C, higher steatosis indices, and higher renal cortical ETAR.
Methodological Strengths
- Endothelial cell–specific genetic model with mechanistic dissection of ET-1–ETAR–ACSS2 cascade
- Pharmacologic reversal with ETAR antagonist and supportive human biopsy correlations
Limitations
- Predominantly murine data; human analyses are correlative and not interventional
- Duration and durability of effects beyond study windows remain to be established
Future Directions: Biomarker-guided clinical trials of ETAR blockade in patients with endothelial damage signatures; exploration of ATM restoration or DNA repair augmentation as upstream interventions.
BACKGROUND: Cardiovascular diseases increase with aging and are closely linked to metabolic dysfunction and kidney disease through the cardiovascular-kidney-metabolic axis, but the underlying molecular mechanisms remain unclear. Accumulating evidence suggests that vascular endothelial cells (ECs) are particularly vulnerable to aging stressors, such as DNA damage. We investigated whether EC DNA damage drives cardiovascular-kidney-metabolic dysfunction. METHODS: We generated mice with EC-specific DNA double-strand breaks using an endonuclease I-PpoI and subjected them to a high-fat diet (HFD). This approach allowed us to investigate the impact of EC-specific DNA damage on cardiovascular, metabolic, and renal systems. Furthermore, we analyzed the correlation between EC DNA damage markers (γH2AX) and clinical parameters in human kidney biopsy samples. RESULTS: High-fat diet-fed endonuclease I-PpoI mice rapidly developed hypertension, dyslipidemia (low high-density lipoprotein cholesterol), hepatic steatosis, and visceral fat accumulation. Mechanistically, high-fat diet feeding compromised DNA repair capacity by suppressing ATM expression in the aorta. Consequently, DNA damage in aortic ECs triggered ET-1 (endothelin-1) secretion. This induced hepatic hypoxia and ETAR (endothelin type A receptor) activation, which promoted lipid metabolic reprogramming via ACSS2 (acetyl-CoA synthetase 2) upregulation. In addition, renal aging was accelerated. The selective ETAR antagonist atrasentan normalized blood pressure, reversed hepatic steatosis, restored high-density lipoprotein cholesterol, reduced visceral fat, and attenuated renal aging. In humans, EC DNA damage correlated negatively with estimated glomerular filtration rate and high-density lipoprotein cholesterol and positively with hepatic steatosis indices and renal cortical ETAR expression. CONCLUSIONS: Endothelial DNA damage is a pivotal driver of cardiovascular-kidney-metabolic dysfunction through the ET-1-ETAR-ACSS2 signaling cascade. ETAR blockade offers a mechanism-based therapeutic strategy for age-related cardiovascular, renal, and metabolic diseases.